Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Study drug 4D-150 for wet macular degeneration not responding enough
This early-stage study tests 4D-150 (a one-time injection into the eye) for “wet” age-related macular degeneration to see if it can better control leaking blood vessel growth and reduce fluid. It’s for people who are already getting anti-VEGF injections but still need ongoing treatment because of signs of fluid on special eye scans.
Phoenix, ArizonaAges 50 years+ - NCT07587515RecruitingPhase 1/Phase 2
New Eye Drop Treatment for Wet Age-Related Macular Degeneration
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Beverly Hills, CaliforniaAges 50 years+ - NCT07330674RecruitingPhase 1
Safety study of ABF-101 in healthy people and AMD patients
This trial tests the safety of a new drug called ABF-101 in two groups: healthy volunteers (Part A and B) and people with age-related macular degeneration (AMD, Part C). If you join, you will help researchers understand how the drug affects the body and if it's safe enough to study further.
Dallas, TexasAges 18–50 - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT06351605Recruiting
Light therapy study for dry age-related macular degeneration
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
OsloAges Any age - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT07441642RecruitingPhase 2
Testing FWY003 eye drops for geographic atrophy (dry AMD)
This trial tests a new eye drop called FWY003 against a placebo (an inactive drop) to see if it can slow the progression of geographic atrophy (the dry form of age-related macular degeneration). It may help people who have moderate vision loss from this condition.
Huntington Beach, CaliforniaAges 50 years+ - NCT06924021Recruiting
AMD Eye Image Library (ABID) Study
This study is creating a library of eye images to help doctors better diagnose age-related macular degeneration (AMD). You can join if you have healthy eyes or any stage of AMD that has never been treated.
Fargo, North DakotaAges 50 years+ - NCT07660640Enrolling by invitation
Long-term follow-up for VOY-101 eye injection study
This study follows up with people who already received the VOY-101 injection for a type of age-related vision loss (non-neovascular age-related macular degeneration) in an earlier study. It checks how they are doing over a longer period of time.
Boston, MassachusettsAges 50 years+ - NCT06355830Recruiting
A study of intermediate age-related macular degeneration
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
LisbonAges 55–95 - NCT07249216Recruiting
Eye fluid study for wet AMD treatment response
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
SingaporeAges 50 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT06031727RecruitingEarly Phase 1
CRISPR gene therapy for wet age-related macular degeneration
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Poway, CaliforniaAges 55 years+ - NCT03577041Recruiting
Cost study of eye injections for new macular degeneration
This study evaluates the cost-effectiveness of three anti-VEGF eye injection treatments (bevacizumab, ranibizumab, or aflibercept) for patients with newly diagnosed age-related macular degeneration affecting the center of vision. The research aims to understand which treatment option provides the best medical and financial value in France.
AmiensAges 18–70 - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Mesa, ArizonaAges 50 years+ - NCT05706896Recruiting
Cord blood plasma injections for dry macular degeneration
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
RomeAges 65 years+ - NCT06536062Recruiting
Cord blood and platelet plasma for dry macular degeneration
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
Rome, RomeAges 65 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT07680244Recruiting
Testing a new tool to see retina in eye scans
This trial is testing a new software tool that helps doctors see and assess different parts of the retina in eye scans. It aims to see how well the tool works in people with and without certain retina conditions.
Tucson, ArizonaAges 18 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 168 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.